{
  "id": "5a723edd2dc08e987e00000c",
  "type": "yesno",
  "question": "Is Tofacitinib effective for Ulcerative Colitis?",
  "ideal_answer": "Yes. Tofacitinib, an oral small-molecule Janus kinase inhibitor, is effective in the treatment of moderate-severe ulcerative colitis. It is also effective treatment of rheumatoid arthritis and autoimmune encephalomyelitis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
    "http://www.ncbi.nlm.nih.gov/pubmed/28164724",
    "http://www.ncbi.nlm.nih.gov/pubmed/27663846",
    "http://www.ncbi.nlm.nih.gov/pubmed/28503977",
    "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
    "http://www.ncbi.nlm.nih.gov/pubmed/28158411",
    "http://www.ncbi.nlm.nih.gov/pubmed/27140405",
    "http://www.ncbi.nlm.nih.gov/pubmed/27699641",
    "http://www.ncbi.nlm.nih.gov/pubmed/28601639",
    "http://www.ncbi.nlm.nih.gov/pubmed/28790099",
    "http://www.ncbi.nlm.nih.gov/pubmed/25651782",
    "http://www.ncbi.nlm.nih.gov/pubmed/28475384",
    "http://www.ncbi.nlm.nih.gov/pubmed/26608188"
  ],
  "snippets": [
    {
      "text": "Tofacitinib, inhibiting signalling via all Janus kinase family members, was effective in phase 2 and 3 trials in moderate-severe ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158411",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Among them, Janus kinase (JAK) inhibitors seem to have the lead, since tofacitinib has received regulatory approval in 2012 for the treatment of rheumatoid arthritis, and also it has shown a favorable risk-benefit ratio in phase 3 studies for ulcerative colitis, both in anti-TNF na\u00efve and anti-TNF experienced patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28164724",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Near future conventional drug options include oral agents such as tofacitinib and mongersen. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28475384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tofacitinib showed dose related efficacy for induction therapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28503977",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tofacitinib (CP-690,550), an oral small-molecule Janus kinase inhibitor, has been shown to be effective in the treatment of rheumatoid arthritis, autoimmune encephalomyelitis and ulcerative colitis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28601639",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>BACKGROUND</b>: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Across all three trials, adjudicated nonmelanoma skin cancer occurred in five patients who received tofacitinib and in one who received placebo, and adjudicated cardiovascular events occurred in five who received tofacitinib and in none who received placebo; as compared with placebo, tofacitinib was associated with increased lipid levels.<br><b>CONCLUSIONS</b>: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tofacitinib (CP-690,550), an oral small-molecule Janus kinase inhibitor, has been shown to be effective in the treatment of rheumatoid arthritis, autoimmune encephalomyelitis and ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28601639",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Tofacitinib, a non-selective Janus kinase (JAK) inhibitor, is effective in inducing clinical and endoscopic remission in patients with active ulcerative colitis (UC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28790099",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25651782",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tofacitinib, an oral janus kinase inhibitor, is a new biologic that has shown promise in the treatment of ulcerative colitis and may be effective in the treatment of Crohn's disease according to phase 2 trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27663846",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Three patients treated with tofacitinib had an absolute neutrophil count of less than 1500.<br><b>CONCLUSIONS</b>: Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tofacitinib an oral small molecule janus kinase inhibitor was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial we further evaluated the efficacy of tofacitinib as induction and maintenance therapy we conducted three phase 3 randomized double blind placebo controlled trials of tofacitinib therapy in adults with ulcerative colitis in the octave induction 1 and 2 trials 598 and 541 patients respectively who had moderately to severely active ulcerative colitis despite previous conventional therapy or therapy with a tumor necrosis factor antagonist were randomly assigned to receive induction therapy with tofacitinib 10 mg twice daily or placebo for 8 weeks the primary end point was remission at 8 weeks in the octave sustain trial 593 patients who had a clinical response to induction therapy were randomly assigned to receive maintenance therapy with tofacitinib either 5 mg or 10 mg twice daily or placebo for 52 weeks the primary end point was remission at 52 weeks in the octave induction 1 trial remission at 8 weeks occurred in 18 5 of the patients in the tofacitinib group versus 8 2 in the placebo group p 0 007 in the octave induction 2 trial remission occurred in 16 6 versus 3 6 p 0 001 in the octave sustain trial remission at 52 weeks occurred in 34 3 of the patients in the 5 mg tofacitinib group and 40 6 in the 10 mg tofacitinib group versus 11 1 in the placebo group p 0 001 for both comparisons with placebo in the octave induction 1 and 2 trials the rates of overall infection and serious infection were higher with tofacitinib than with placebo in the octave sustain trial the rate of serious infection was similar across the three treatment groups and the rates of overall infection and herpes zoster infection were higher with tofacitinib than with placebo across all three trials adjudicated nonmelanoma skin cancer occurred in five patients who received tofacitinib and in one who received placebo and adjudicated cardiovascular events occurred in five who received tofacitinib and in none who received placebo as compared with placebo tofacitinib was associated with increased lipid levels in patients with moderately to severely active ulcerative colitis tofacitinib was more effective as induction and maintenance therapy than placebo funded by pfizer octave induction 1 octave induction 2 and octave sustain clinicaltrials gov numbers nct01465763 nct01458951 and nct01458574 respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective one additional treatment may be tofacitinib cp 690 550 an oral inhibitor of janus kinases 1 2 and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2 which is expected to block signaling involving gamma chain containing cytokines including interleukins 2 4 7 9 15 and 21 these cytokines are integral to lymphocyte activation function and proliferation in a double blind placebo controlled phase 2 trial we evaluated the efficacy of tofacitinib in 194 adults with moderately to severely active ulcerative colitis patients were randomly assigned to receive tofacitinib at a dose of 0 5 mg 3 mg 10 mg or 15 mg or placebo twice daily for 8 weeks the primary outcome was a clinical response at 8 weeks defined as an absolute decrease from baseline in the score on the mayo scoring system for assessment of ulcerative colitis activity possible score 0 to 12 with higher scores indicating more severe disease of 3 or more and a relative decrease from baseline of 30 or more with an accompanying decrease in the rectal bleeding subscore of 1 point or more or an absolute rectal bleeding subscore of 0 or 1 the primary outcome clinical response at 8 weeks occurred in 32 48 61 and 78 of patients receiving tofacitinib at a dose of 0 5 mg p 0 39 3 mg p 0 55 10 mg p 0 10 and 15 mg p 0 001 respectively as compared with 42 of patients receiving placebo clinical remission defined as a mayo score 2 with no subscore 1 at 8 weeks occurred in 13 33 48 and 41 of patients receiving tofacitinib at a dose of 0 5 mg p 0 76 3 mg p 0 01 10 mg p 0 001 and 15 mg p 0 001 respectively as compared with 10 of patients receiving placebo there was a dose dependent increase in both low density and high density lipoprotein cholesterol three patients treated with tofacitinib had an absolute neutrophil count of less than 1500 patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo funded by pfizer clinicaltrials gov number nct00787202.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "recently several medical treatments for ulcerative colitis uc have been developed including 5 aminosalicylic acids 5 asas corticosteroids thiopurine calcineurin inhibitors and anti tumor necrosis factor tnf \u03b1 treatments treatment options including calcineurin inhibitors and anti tnf treatment for refractory uc are discussed in this article furthermore upcoming treatments are introduced such as golimumab vedolizumab ajm300 tofacitinib budesonide foamwill be used as one treatment option in patients with distal colitis herbal medicine such as qing dai is also effective for active uc and may be useful for patients who are refractory to anti tnf\u03b1 treatments in the near future physicians will able to use many different treatments for uc patients however we should not forget 5 asa and corticosteroids as the fundamental treatments for uc patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27699641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "the inflammatory diseases ulcerative colitis and crohn s disease constitute the two main forms of inflammatory bowel disease ibd they are characterized by chronic relapsing inflammation of the gastrointestinal tract significantly impacting on patient quality of life and often requiring prolonged treatment existing therapies for ibd are not effective for all patients and an unmet need exists for additional therapies to induce and maintain remission here we describe the mechanism of action of the janus kinase jak inhibitor tofacitinib for the treatment of ibd and the effect of jak inhibition on the chronic cycle of inflammation that is characteristic of the disease the pathogenesis of ibd involves a dysfunctional response from the innate and adaptive immune system resulting in overexpression of multiple inflammatory cytokines many of which signal through jaks thus jak inhibition allows multiple cytokine signaling pathways to be targeted and is expected to modulate the innate and adaptive immune response in ibd thereby interrupting the cycle of inflammation tofacitinib is an oral small molecule jak inhibitor that is being investigated as a targeted immunomodulator for ibd clinical development of tofacitinib and other jak inhibitors is ongoing with the aspiration of providing new treatment options for ibd that have the potential to deliver prolonged efficacy and clinically meaningful patient benefits.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26608188",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.disease-ontology.org/api/metadata/DOID:8577",
    "https://meshb.nlm.nih.gov/record/ui?ui=D016896",
    "https://meshb.nlm.nih.gov/record/ui?ui=D003093"
  ],
  "exact_answer": "Yes"
}